Neurones (NRO) Q3 2026 TU earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 TU earnings summary
4 Nov, 2026Executive summary
Q3 2026 revenue grew 7.1% organically, with momentum accelerating versus the prior year; the full-year operating income target was raised to above 9%.
Financial highlights
Q3 revenue was €222.6m vs. €207.9m in Q3 2025, up 7.1% reported and organically.
9M revenue was €677.4m vs. €632.2m, up 7.1% reported and 6.9% organically.
Outlook and guidance
FY operating income target raised to above 9%; revenue guidance reaffirmed at more than €900m.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Neurones
- H1 2026 revenue up 7.2% to €454.8M; net income €31.2M; strong outlook for full year.NRO
H1 2026 - Organic growth hit 8% in Q2 2026, boosting H1 revenues and profit margin year-over-year.NROQ2 2026 TU
- Q1 2026 delivered 5.6% organic growth and a higher 9% operating margin, led by digital projects.NROQ1 2026 TU
- 2025 revenue up 5.8%, operating margin at 10.4%, and dividend set to rise 7.7%.NROH2 2025
- Revenue up 5.8% to €857.2M in 2025, with strong digital, data, and AI growth.NROQ4 2025 TU
- Q3 2025 delivered 5.1% organic growth and improved margins, with robust digital segment gains.NROQ3 2025
- Revenue up 5.4% to €424.3M; margin improved; FY guidance raised to €850M.NROH1 2025
- Organic growth of 5.3% in Q2 2025 drives raised full-year revenue guidance.NROQ2 2025 TU
- Revenue up 9.1% to €402.4M, net income €29.2M, and 2024 guidance for €800M reaffirmed.NROH1 2024